Spartan Bioscience Gets CE IVD Mark for 'Sample-to-Answer' CYP2C19 Testing Platform

Spartan has already sold four systems to undisclosed customers in Europe and is "very close" to signing its first distribution agreement on the continent for the Spartan Rx CYP2C19 test, the company's CEO said.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.